1. Home
  2. TVGN vs NCEL Comparison

TVGN vs NCEL Comparison

Compare TVGN & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

SELL

Current Price

$6.10

Market Cap

21.3M

Sector

Finance

ML Signal

SELL

Logo NewcelX Ltd. Ordinary Shares

NCEL

NewcelX Ltd. Ordinary Shares

SELL

Current Price

$2.67

Market Cap

19.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TVGN
NCEL
Founded
2020
2008
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3M
19.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
TVGN
NCEL
Price
$6.10
$2.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.8K
★ 14.3K
Earning Date
11-16-2026
09-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$1.83
52 Week High
$24.91
$5.12

Technical Indicators

Market Signals
Indicator
TVGN
NCEL
Relative Strength Index (RSI) 48.25 46.22
Support Level $5.01 $2.32
Resistance Level $7.22 $3.22
Average True Range (ATR) 0.42 0.25
MACD 0.08 0.01
Stochastic Oscillator 53.23 43.03

Price Performance

Historical Comparison
TVGN
NCEL

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: